ArticleCurrent oncology (Toronto, Ont.)2017
Carcinoma ex pleomorphic adenoma: case report and options for systemic therapy.
Article in Current oncology (Toronto, Ont.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 21 citations in OpenAlex.
- Case Report: Carcinoma Ex-Pleomorphic Adenoma With Concurrent Submandibular Gland Lithiasis-A Rare Association With Potential Pathophysiological Implications.Clinical case reports · 2025Article
- ECT2NPJ precision oncology · 2025Article
- Assessment of Parotid Gland Tumors by Means of Quantitative Multiparametric Ultrasound (mpUS).Diagnostics (Basel, Switzerland) · 2022Article
- Pleomorphic Adenoma of the Parotid Gland and Ipsilateral Thyroid Incidentaloma: Report of A Rare Case With Review of Literature.Translational medicine @ UniSa · 2020Article
- Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes.Nature cancer · 2020Article
- Carcinoma ex pleomorphic adenoma: a case report and review of literature.African health sciences · 2019Review
- Carcinoma ex pleomorphic adenoma of the trachea: A case report.World journal of clinical cases · 2019Article
- Anlotinib is effective in the treatment of advanced carcinoma ex pleomorphic adenoma of the submandibular gland.OncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common benign salivary tumour is a pleomorphic adenoma. Transformation to malignancy, carcinoma ex pleomorphic adenoma (cxpa), occurs in 6% of cases. Management focuses on surgical resection and radiotherapy; however, rare cases require systemic management. We present the case of a 60-year-old woman with a cxpa of the left parotid gland who required systemic therapy for locally recurrent disease. Treatment options were guided by the literature concerning malignant salivary gland tumour and by whole-genome and transcriptome sequencing of the tumour. The patient received multiple systemic agents during the course of her disease, with cyclophosphamide-doxorubicin-cisplatin providing the best control (partial response). Genomeand transcriptome-directed therapy, including sorafenib and vismodegib, were utilized with limited clinical benefit. Malignant transformation in cxpa is a complex process, and therapy directed at a single tumour pathway might not be sufficient to control disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.